
Academic Journal
Q1Theranostics
About Theranostics
Theranostics is a scholarly journal published by Ivyspring International Publisher. SCImago 2025 places it in - with an SJR of not reported and an H-index of 199.
Its listed coverage is 2011-2025 and its research categories include Medicine (miscellaneous); Pharmacology, Toxicology and Pharmaceutics (miscellaneous). The 2025 dataset reports 447 documents and 18471 citations across the latest three-year reporting window.
Theranostics, a fusion of "therapy" and "diagnostics," is an emerging field that combines diagnostic tools with therapeutic applications. This innovative approach is transforming the landscape of medicine, providing a more personalized, targeted treatment for patients. By integrating diagnostic tests with therapeutic treatments, theranostics enables healthcare professionals to detect diseases earlier, understand their progression, and deliver treatments that are precisely tailored to each patient's needs.
What is Theranostics?
Theranostics refers to the use of specific diagnostic tests to identify patients who will most likely benefit from certain therapies. It involves the development of biomarkers—biological indicators—that help in the diagnosis and treatment of diseases such as cancer, cardiovascular diseases, and neurological disorders. Theranostics goes beyond traditional medicine, which generally separates diagnosis and treatment into two distinct stages. Instead, it enables real-time monitoring and targeted therapy, improving patient outcomes significantly.
The Role of Theranostics in Cancer Treatment
One of the most notable applications of theranostics is in oncology, where it is revolutionizing cancer treatment. Cancer therapies often require identifying specific molecular characteristics of the tumor, such as genetic mutations or protein expressions, to choose the most effective treatment.
Theranostic approaches use targeted imaging techniques like PET scans or MRI combined with molecular markers to identify and locate tumors with high precision. Once the tumor is located, theranostics facilitates the use of targeted therapies, such as radiopharmaceuticals or monoclonal antibodies, designed to specifically attack the cancer cells while minimizing damage to healthy tissues. This minimizes side effects and improves the effectiveness of treatment.
Theranostics and Personalized Medicine
Personalized medicine aims to tailor treatments to individual patients based on their unique genetic and molecular profiles. Theranostics plays a crucial role in this concept, as it helps doctors determine the best course of treatment for each patient. By using diagnostic techniques to analyze biomarkers, healthcare providers can make informed decisions about which therapy is likely to yield the best results.
For example, in precision oncology, theranostics helps doctors select targeted therapies based on the genetic mutations present in a patient's cancer cells. This not only improves treatment outcomes but also reduces the likelihood of unnecessary treatments or side effects, optimizing the patient's overall health and well-being.
Advancements in Theranostics Technology
The development of new technologies has significantly advanced the theranostics field. Innovations in imaging techniques, such as functional MRI and molecular imaging, allow for better visualization of the disease's location and progression. Additionally, the creation of advanced biomarkers and radiopharmaceuticals has improved the accuracy of diagnosis and the efficiency of therapy.
Moreover, theranostics is not just limited to cancer. In the field of neurology, theranostics is being used to detect early signs of neurodegenerative diseases such as Alzheimer’s and Parkinson's. By utilizing imaging techniques and biomarkers, healthcare providers can identify patients at risk and implement early interventions, potentially slowing the disease’s progression.
The Future of Theranostics
The future of theranostics is promising, with ongoing research focused on expanding its applications across various medical fields. As technology advances, theranostics will continue to evolve, offering more effective and targeted treatments. The integration of artificial intelligence and machine learning into theranostic processes will further enhance the precision and efficiency of diagnostics and therapy, ultimately improving patient outcomes.
In conclusion, theranostics represents a significant leap forward in personalized medicine. By combining diagnostic and therapeutic techniques, it offers a highly individualized approach to patient care, improving both the accuracy of diagnosis and the effectiveness of treatment. As research in this field continues to progress, theranostics has the potential to transform the way we approach medicine, leading to better outcomes and healthier lives.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Theranostics is a rapidly emerging field in modern medicine that combines therapeutic and diagnostic capabilities into a single platform. This integrated approach is transforming healthcare by enabling more personalized, efficient, and effective treatments. As the world’s healthcare system continues to evolve, the scope of theranostics is expanding across various medical disciplines, especially in oncology, neurology, and cardiovascular diseases.
What is Theranostics?
Theranostics is the fusion of therapeutic and diagnostic technologies. It involves the use of diagnostic tests to identify the presence of a disease or medical condition, followed by targeted therapeutic interventions. By combining these elements, theranostics allows doctors to tailor treatment strategies to the specific needs of the patient, enhancing both the precision and effectiveness of medical care.
Key Areas of Theranostic Application
-
Oncology (Cancer Treatment) One of the most significant areas where theranostics is making an impact is in the treatment of cancer. Theranostics allows for the identification of specific tumor markers through imaging techniques, such as PET scans or MRI, followed by targeted therapies. This combination helps ensure that cancer treatments, such as radiation therapy or chemotherapy, are delivered precisely to the tumor site, minimizing damage to surrounding healthy tissues. Additionally, the use of theranostics enables doctors to monitor the treatment’s progress in real-time, making adjustments as needed.
-
Neurology In the field of neurology, theranostics is revolutionizing the diagnosis and treatment of neurological disorders like Alzheimer’s disease, Parkinson’s disease, and epilepsy. Using molecular imaging and biomarkers, doctors can identify the presence of neurological diseases at an early stage, allowing for timely intervention. Targeted drug delivery systems in theranostics help in ensuring that the drugs reach the right part of the brain, improving therapeutic outcomes.
-
Cardiovascular Diseases Theranostics has a growing role in cardiovascular medicine, where it is used to detect early signs of heart disease and monitor the effectiveness of treatment options. Advanced imaging techniques, such as molecular imaging, help in assessing the condition of blood vessels, heart tissues, and plaques, enabling healthcare providers to choose the most effective therapeutic strategies for patients.
Benefits of Theranostics
-
Personalized Medicine: One of the greatest advantages of theranostics is its ability to personalize treatment. By identifying specific molecular markers, doctors can prescribe the most appropriate treatment tailored to the individual patient’s needs.
-
Reduced Side Effects: Targeted therapies in theranostics are designed to minimize damage to healthy tissues, reducing side effects often seen with traditional treatments like chemotherapy or radiation therapy.
-
Improved Diagnosis and Monitoring: Theranostic techniques provide more accurate and timely diagnoses, allowing for early intervention. Additionally, they enable continuous monitoring of a patient’s response to treatment, improving the overall quality of care.
Future of Theranostics
As technology continues to advance, the scope of theranostics is set to grow. Innovations in nanotechnology, molecular imaging, and biomarker identification are expected to drive new developments in the field. Future applications may include even more targeted therapies, allowing for the treatment of rare diseases or conditions previously considered difficult to manage.
Moreover, the integration of artificial intelligence (AI) with theranostics holds the potential to revolutionize how doctors diagnose and treat diseases. AI algorithms can analyze vast amounts of medical data, identifying patterns that may otherwise go unnoticed, leading to more precise treatment decisions.
Recent Research Articles
Latest publications matched automatically by ISSN.
DCTN2 inhibited cellular senescence through targeting TRIM21 mediated MST2 ubiquitination and activation in hepatocellular carcinoma
Yanbo Wang, Yaomei He, Qin Yu, Ningrui Wang et al.
2026-09-03 · DOI: 10.7150/thno.137790A nanoengineered MSC therapeutic for synergistic therapy of lupus nephritis via cfDNA clearance and targeted immunomodulation
Jiang Tian, Qinyao Xu, Zexin Wang, Zeyu Wang et al.
2026-09-03 · DOI: 10.7150/thno.136356Oral inulin prebiotic encapsulating Cortex Fraxini extracellular vesicles alleviates colitis and associated renal stress via reinforcing intestinal barriers and remodeling microbiota
Meihong Chai, Junlong Fu, Mengjie Zhang, Xing Pei et al.
2026-09-02 · DOI: 10.7150/thno.139484Visualizing the distribution of durvalumab targeting PD-L1 using quantitative fluorescence imaging in patients with esophageal cancer
Anne M. van der Waaij, Ymke J. van Ginkel, Pia Volkmer, Gursah Kats-Ugurlu et al.
2026-09-02 · DOI: 10.7150/thno.136523Atherosclerosis nanotheranostics: a perspective from macrophages
Caiyan Zhao, Jiakun Zhang, Rujie Wang, Shen’ao Wang et al.
2026-09-02 · DOI: 10.7150/thno.121239Microbial enzyme-responsive inulin nanoparticles for colon-targeted oral delivery of 5-ASA toward improved therapy of inflammatory bowel disease
Haena Park, Panmo Son, Chiwoo Oh, Hyeryeon Oh et al.
2026-08-24 · DOI: 10.7150/thno.127560Nano-flow intracalvariosseous infusion enables skull-to-brain delivery of BBB-impermeable molecular and nanoscale agents in mice and rabbits
Ji Hee Kang, O Hyun Lee, Min Suk Shim, Sehoon Kim et al.
2026-08-24 · DOI: 10.7150/thno.138110mRNA-dendritic cell antigen vaccine potentiates CD38 CAR-T Cell therapy for relapsed/refractory acute myeloid leukemia
Yu Lu, Xin Cai, Yanhui Li, Yuyuan Lv et al.
2026-08-24 · DOI: 10.7150/thno.139339Towards practical radiopharmaceutical treatment planning: a review of dosimetry simplification techniques
Elmira Yazdani, Zahra Mansouri, Yazdan Salimi, Habib Zaidi et al.
2026-08-24 · DOI: 10.7150/thno.1325383D vascular mapping reveals multi-organ injury following severe acute pancreatitis
Xiaomei Liu, Jingtan Zhu, Qiao Shi, Jianyi Xu et al.
2026-08-24 · DOI: 10.7150/thno.141299Preclinical efficacy and dosimetry of CD44v6-directed terbium-161 radionuclide therapy
Amanda Gustafsson, Anja Charlotte Lundgren Mortensen, Veronica Rondahl, Tianqi Xu et al.
2026-08-24 · DOI: 10.7150/thno.135243EBDE clearing: A strategy for simultaneous 3D visualization and quantitative analysis of both renal arteries and glomeruli
Yaping Wu, Qian Shen, Yan Liang, Lin Bai et al.
2026-08-24 · DOI: 10.7150/thno.138951Colon-targeted oral delivery of melatonin for regulating macrophage activity and intestinal barrier in ulcerative colitis
Nhu-Nam Nguyen, Yoojin Seo, Tiep Tien Nguyen, Kim-Phuong Phan et al.
2026-08-24 · DOI: 10.7150/thno.133456Feedback-regulated 3D-printed hydrogel micropatch for integrated therapy of fungal keratitis
Yujie Liu, Li Ma, Guodong Fang, Tan Li et al.
2026-08-24 · DOI: 10.7150/thno.134232Engineered nanomedicine remodels the postoperative cavity microenvironment to suppress glioblastoma recurrence
Zhiqun Bai, Zhiguang Chen
2026-08-24 · DOI: 10.7150/thno.141774Spatiotemporally programmed hybrid nano-prodrugs orchestrate multidimensionally synergistic cascade lethality in NSCLC
Yan Wang, Chaozheng Zhang, Chen Sun, Yao Chen et al.
2026-08-24 · DOI: 10.7150/thno.135204Targeted phagocytosis of TNF-α by CAR macrophages restores immune homeostasis in arthritis
Mei-Qi Wang, Jie Zhu, Chun-Yu Liu, Xiao-Lin Yu et al.
2026-08-24 · DOI: 10.7150/thno.132172Membrane and soluble VTCN1 (B7H4) converge on Src signaling to mediate gemcitabine resistance in intrahepatic cholangiocarcinoma
Yi-Ru Pan, Sheng-Hsuan Lin, Yu-Chan Chang, Shih-Ming Jung et al.
2026-08-24 · DOI: 10.7150/thno.130394hNET-targeted [ 18 F]MFBG PET as baseline functional imaging in newly diagnosed neuroblastoma
Lifeng Zhang, Xinhui Su, Xinyue Zheng, En Ren et al.
2026-08-24 · DOI: 10.7150/thno.139324Targeted molecular CT imaging of atherosclerosis and abdominal aortic aneurysm
Jannis Marchand, Felix Stefan Reuter, Hannah Lichtmannegger, Keno Kyrill Bressem et al.
2026-08-24 · DOI: 10.7150/thno.137688Reviews
Community Reviews
Version History
April 23, 2025 at 11:26 am
April 23, 2025